Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways.
Monte Rosa Therapeutics has raised $300.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2026.
Monte Rosa Therapeutics's investors include BlackRock, New Enterprise Associates, Cormorant Asset Management, Versant Ventures, Fidelity.
Monte Rosa Therapeutics is headquartered in Basel, Switzerland.
Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways.
Monte Rosa Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Monte Rosa Therapeutics — Funding & Investors." VCBacked, January 8, 2026, https://www.vcbacked.co/company/monte-rosa-therapeutics. Accessed October 17, 2026.
VCBacked. (2026). Monte Rosa Therapeutics — Funding & Investors. Retrieved October 17, 2026, from https://www.vcbacked.co/company/monte-rosa-therapeutics
{{cite web |title=Monte Rosa Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/monte-rosa-therapeutics |website=VCBacked |access-date=October 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated